196 related articles for article (PubMed ID: 27822706)
1. Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.
Dragoj M; Milosevic Z; Bankovic J; Tanic N; Pesic M; Stankovic T
Cell Oncol (Dordr); 2017 Feb; 40(1):47-62. PubMed ID: 27822706
[TBL] [Abstract][Full Text] [Related]
2. Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.
Dragoj M; Bankovic J; Sereti E; Stojanov SJ; Dimas K; Pesic M; Stankovic T
Invest New Drugs; 2017 Dec; 35(6):718-732. PubMed ID: 28733702
[TBL] [Abstract][Full Text] [Related]
3. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers.
Chen YL; Yang TY; Chen KC; Wu CL; Hsu SL; Hsueh CM
Cell Oncol (Dordr); 2016 Oct; 39(5):411-433. PubMed ID: 27306525
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells.
Su L; Zhang J; Xu H; Wang Y; Chu Y; Liu R; Xiong S
Clin Cancer Res; 2005 Dec; 11(23):8273-80. PubMed ID: 16322285
[TBL] [Abstract][Full Text] [Related]
6. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
[TBL] [Abstract][Full Text] [Related]
7. Visfatin mediates doxorubicin resistance in human non-small-cell lung cancer via Akt-mediated up-regulation of ABCC1.
Cao Z; Liang N; Yang H; Li S
Cell Prolif; 2017 Oct; 50(5):. PubMed ID: 28762597
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.
Fahham D; Weiss ID; Abraham M; Beider K; Hanna W; Shlomai Z; Eizenberg O; Zamir G; Izhar U; Shapira OM; Peled A; Wald O
J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1167-1175.e1. PubMed ID: 22925564
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Potential of Focal Adhesion Kinase Inhibition in Small Cell Lung Cancer.
Aboubakar Nana F; Lecocq M; Ladjemi MZ; Detry B; Dupasquier S; Feron O; Massion PP; Sibille Y; Pilette C; Ocak S
Mol Cancer Ther; 2019 Jan; 18(1):17-27. PubMed ID: 30352800
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin.
Mei L; Liu Y; Zhang Q; Gao H; Zhang Z; He Q
J Control Release; 2014 Dec; 196():324-31. PubMed ID: 25450404
[TBL] [Abstract][Full Text] [Related]
11. Selective targeting of FAK-Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells.
Datta A; Bhasin N; Kim H; Ranjan M; Rider B; Abd Elmageed ZY; Mondal D; Agrawal KC; Abdel-Mageed AB
Cancer Lett; 2015 Jun; 362(1):25-35. PubMed ID: 25796439
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
13. Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations.
Bao YX; Zhao XD; Deng HB; Lu CL; Guo Y; Lu X; Deng LL
Cell Oncol (Dordr); 2016 Aug; 39(4):343-52. PubMed ID: 27016208
[TBL] [Abstract][Full Text] [Related]
14. Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway.
Fu QF; Liu Y; Fan Y; Hua SN; Qu HY; Dong SW; Li RL; Zhao MY; Zhen Y; Yu XL; Chen YY; Luo RC; Li R; Li LB; Deng XJ; Fang WY; Liu Z; Song X
J Hematol Oncol; 2015 Mar; 8():22. PubMed ID: 25887760
[TBL] [Abstract][Full Text] [Related]
15. Reversal of cisplatin resistance in non-small cell lung cancer stem cells by Taxus chinensis var.
Jiang YQ; Xu XP; Guo QM; Xu XC; Liu QY; An SH; Xu JL; Su F; Tai JB
Genet Mol Res; 2016 Sep; 15(3):. PubMed ID: 27706681
[TBL] [Abstract][Full Text] [Related]
16. miR-199a-5p is involved in doxorubicin resistance of non-small cell lung cancer (NSCLC) cells.
Jin Y; Wang H; Zhu Y; Feng H; Wang G; Wang S
Eur J Pharmacol; 2020 Jul; 878():173105. PubMed ID: 32278855
[TBL] [Abstract][Full Text] [Related]
17. Enterolactone alters FAK-Src signaling and suppresses migration and invasion of lung cancer cell lines.
Chikara S; Lindsey K; Borowicz P; Christofidou-Solomidou M; Reindl KM
BMC Complement Altern Med; 2017 Jan; 17(1):30. PubMed ID: 28068967
[TBL] [Abstract][Full Text] [Related]
18. The role of PTPN13 in invasion and metastasis of lung squamous cell carcinoma.
Han X; Xue L; Zhou L; Gong L; Zhu S; Yao L; Wang S; Lan M; Li Y; Zhang W
Exp Mol Pathol; 2013 Dec; 95(3):270-5. PubMed ID: 23906871
[TBL] [Abstract][Full Text] [Related]
19. Acacetin enhances the therapeutic efficacy of doxorubicin in non-small-cell lung carcinoma cells.
Punia R; Raina K; Agarwal R; Singh RP
PLoS One; 2017; 12(8):e0182870. PubMed ID: 28859099
[TBL] [Abstract][Full Text] [Related]
20. Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer.
Wang S; Pan H; Liu D; Mao N; Zuo C; Li L; Xie T; Huang D; Huang Y; Pan Q; Yang L; Wu J
Int J Oncol; 2015 Feb; 46(2):809-17. PubMed ID: 25434755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
